A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Active:	No
Cancer Type:	Colon/Rectal Cancer Liver Cancer / Hepatoblastoma Melanoma	NCT ID:	NCT03656718
Trial Phases:	Phase I Phase II	Protocol IDs:	CA209-8KX (primary) NCI-2018-02324 2018-001585-42
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	http://clinicaltrials.gov/show/NCT03656718

Summary

The purpose of this study is to investigate the effects of nivolumab when given under the
skin with or without rHuPH20.

This study will include participants with 1 of the following advanced or metastatic
tumors approved for treatment with nivolumab monotherapy:

- non-small cell lung cancer (NSCLC)

- renal cell carcinoma (RCC)

- unresectable or metastatic melanoma

- hepatocellular carcinoma (HCC)

- microsatellite instability-high or mismatch repair deficient colorectal cancer
(MSI-H/dMMR CRC)

- in Part B, other solid tumors may be considered at the discretion of the Clinical
Trial Physician

- In addition to the above tumors, Part E will also include participants with
metastatic urothelial carcinoma (mUC).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.